FLT3 and acute myeloid leukemia: To test the robustness of our GRN construction, we determined the complete FLT3-ITD+ AML-specific GRN compared to healthy CD34+ mobilized peripheral blood stem cells (PBSCs) for each of nine patients, as outlined in Figure S1B, and we measured the number of FLT3-ITD+ AML-specific edges found in each patient network but not in healthy cells.